This Hospital Network Stock Rises 187% in 5 Years: Can the Bed Expansion Revive the Rally?

This hospital network stock has turned Rs 1 lakh into roughly Rs 2.87 lakh over five years. A Delhi-headquartered chain of super-specialty hospitals delivered a 5-year return of 187.42% as of 10 September 2026, ranking 40th in a screen of 101 large-cap and mid-cap NSE shares.

The company is Max Healthcare Institute Ltd (NSE: MAXHEALTH), one of India's largest private hospital operators by market value. The Max Healthcare share price closed at approximately Rs 1,039 on 10 September 2026, up from around Rs 360 five years earlier, giving the company a market value of approximately Rs 1,00,884 crore. The last 12 months, however, have been weak for this hospital network stock, and this article covers both sides.

Click Here – Get Free Investment Predictions

How Much Has This Hospital Network Stock Gained in 5 Years?

This hospital network stock has gained approximately 187% in five years, placing it 40th out of 101 screened NSE stocks. That works out to a compound annual return of roughly 23.5%, a strong pace for a company of this size.

The shorter periods tell a very different story for this hospital network stock. The 1-year return is negative at -7.74%, ranking 94th, and the 1-month gain of 0.21% ranks 95th. Here is how this hospital network stock has performed across time frames in our screen:

Period	Return (%)	Rank (out of 101)
1 Month	0.21%	95
6 Months	6.91%	85
1 Year	-7.74%	94
3 Years	81.56%	53
5 Years	187.42%	40

Returns are simple price changes and are not annualised. There was no stock split or bonus issue during the five-year window, so the 187% figure reflects real price appreciation in this hospital network stock. The face value has stayed at Rs 10 per share since listing in August 2020.

The 52-week high of around Rs 1,222 was hit on 23 October 2025, and the 52-week low of around Rs 903 came on 7 April 2026. This hospital network stock is still roughly 15% below that high, even after a 4.5% jump on 9 September 2026.

Why Did This Hospital Network Stock Rise 187% in 5 Years?

This hospital network stock rose 187% because revenue per bed climbed sharply, occupancy stayed high, profits compounded for over five years and the company kept adding beds through new towers and acquisitions. The rally was front-loaded, with most of the gains coming between 2021 and late 2025.

1. Pricing Power: Revenue Per Bed Up Nearly 39%

In the September 2021 quarter, the average revenue per occupied bed (ARPOB) was around Rs 59,000 per day. By Q1 FY27 it had risen approximately 39% to around Rs 81,900. A richer mix of complex cases such as oncology, cardiac sciences, transplants and neurosciences drove most of that gain for this hospital network stock.

International patients have become a steady contributor to this hospital network stock. They brought in about Rs 247 crore in Q1 FY27, up 18% year on year, or roughly 9% of hospital revenue.

2. Earnings Compounded for 22 Straight Quarters

In the first half of FY22, network gross revenue was about Rs 2,819 crore. In Q1 FY27, a single quarter, the company reported approximately Rs 2,982 crore. Full-year FY26 network gross revenue reached Rs 10,538 crore, up 16%, while network profit after tax rose 22% to Rs 1,631 crore.

Q4 FY26 marked the company's 22nd consecutive quarter of year-on-year growth. That consistency is a big reason institutions were willing to pay premium valuations for this hospital network stock.

3. Acquisitions Widened the Map

The company behind this hospital network stock used its strong cash flow to buy hospitals outside its home NCR market. It spent approximately Rs 1,716 crore on the Jaypee Healthcare acquisition during FY25, and in May 2026 it bought a 58.28% stake in Kalinga Hospital, a 250-bed facility in Bhubaneswar, for about Rs 298 crore.

In June 2026 it also acquired full control of Yerawada Properties, where a hospital of around 450 beds is planned in Pune. These deals give this hospital network stock a presence in Uttar Pradesh, Odisha and western India.

4. A Plan to Nearly Double Beds by FY30

The network had around 6,000 beds at the end of FY26, and management targets about 10,000 beds by FY30. Roughly 20% brownfield capacity was commissioned in the six months before May 2026, including a 400-bed tower in Delhi.

New approvals keep coming for this hospital network stock. In May 2026 the board cleared Rs 1,400 crore for a 712-bed greenfield hospital in Lucknow, and in August 2026 it approved Rs 425 crore for a 202-bed tower at Vaishali. Net debt stood at approximately Rs 2,384 crore after Q1 FY27, still well under one times annual EBITDA.

Why Has the Max Healthcare Share Price Fallen Over the Past Year?

The Max Healthcare share price has fallen about 7.74% in one year because profit growth slowed, margins shrank as new beds came online and foreign investors cut their holdings. This hospital network stock had also run up to a rich valuation by October 2025, leaving little room for disappointment.

Q4 FY26 network profit rose only 3% to Rs 387 crore, and Q1 FY27 profit also rose just 3% to Rs 357 crore. Operating margin slipped to 24.8% in Q1 FY27 from 26.8% in the previous quarter. Management blamed costs from newly commissioned beds and the Kalinga integration, which add expenses ahead of full occupancy.

There were one-off hits to this hospital network stock too. In Q3 FY26 the company booked an exceptional charge of about Rs 55 crore linked to new labour codes and stamp duty, and it stopped using certain high-cost patented chemotherapy drugs after pricing curbs under the central government health scheme (CGHS).

Check the Univest Screener for Live Fundamentals of High-Return Stocks

Max Healthcare Financial Performance: Quarterly Trend

The table below shows network figures for this hospital network stock, which include all hospitals operated by the group. Revenue growth has stayed in double digits, but profit growth has slowed sharply over the last two quarters.

Metric (Rs crore)	Q3 FY26	Q4 FY26	Q1 FY27
Network gross revenue	2,608	2,664	2,982
Revenue growth (YoY)	10%	10%	16%
Operating EBITDA	648	682	704
Operating margin	26.1%	26.8%	24.8%
Network PAT	344	387	357
PAT growth (YoY)	9%	3%	3%

Volume held up well for this hospital network stock. Occupied bed days rose 10% year on year in Q1 FY27, occupancy stayed around 75% despite new capacity, and outpatient consultations grew 12% to about 10.5 lakh. Max Lab revenue grew 20% and home care grew 32%.

For this hospital network stock, the gap between 15% EBITDA growth and 3% profit growth likely reflects higher depreciation and interest from new beds and acquisitions. That gap should narrow if the new towers fill up over the next few years.

Is This Hospital Network Stock Expensive?

Yes, by most standard measures this hospital network stock trades at a steep valuation. At around Rs 1,039, it trades at roughly 69 to 70 times trailing earnings, based on trailing earnings per share of approximately Rs 14.91.

That premium has been a feature of this hospital network stock for years. Investors pay for visibility on bed additions, but a high multiple also means the shares can fall sharply when growth slows, as the last year showed.

Hospital Network Stock Shareholding: FIIs Out, Mutual Funds In

The ownership of this hospital network stock has shifted a lot in the last year. Foreign investors have trimmed their holding, while domestic mutual funds and insurers have stepped up buying.

Shareholder	Jun 2025	Jun 2026
Promoter	23.74%	23.71%
FII/FPI	54.76%	41.78%
DII	17.40%	29.96%
Public/Retail	4.09%	4.56%

FII holding in this hospital network stock has dropped from 57.29% in September 2024 to 41.78% in June 2026, which partly explains the weak 1-year return. Mutual funds raised their stake to approximately 18.68% in the June 2026 quarter. Promoter Abhay Soi holds about 23.7%, with no pledged shares.

Key Risks for This Hospital Network Stock

Execution risk is the biggest concern. The company plans to add roughly 4,000 beds by FY30, and every new tower drags on margins until occupancy picks up. Delays or slow ramp-ups would hit returns on capital for this hospital network stock.

Pricing regulation is another risk for this hospital network stock. Government scheme rates, drug pricing rules and any cap on procedure costs can hurt revenue per bed, as the CGHS chemotherapy episode showed in FY26.

Valuation leaves little room for error. Two straight quarters of 3% profit growth have already pulled this hospital network stock well below its October 2025 peak. Competition in the NCR region is also rising as rival chains add beds, and net debt has climbed because of acquisitions.

Download the Univest iOS App or Univest Android App to track the Max Healthcare share price live

Max Healthcare Share: Analyst View

Brokerages remain largely positive on this hospital network stock even after the soft Q1 FY27 profit. Most reports issued in mid-August 2026 kept buy or add ratings but trimmed estimates to reflect higher costs from the new bed pipeline.

One domestic brokerage expects revenue to grow at approximately 22% a year from FY26 to FY29 on the back of higher occupancy. Another expects capacity to nearly double to about 9,400 beds by FY30 and sees the CGHS rate revision as a near-term positive.

Max Healthcare Share Price Target

Verified Max Healthcare share price target figures after Q1 FY27 fall in a narrow band. Domestic brokerages set targets of Rs 1,120, Rs 1,150 and Rs 1,162, with two of them cutting their targets by 3% to 8%. The average target across about 28 analysts is approximately Rs 1,169.

Against the 10 September close of around Rs 1,039, the average Max Healthcare share price target implies upside of roughly 12%. For context, this hospital network stock would need to climb about 18% to revisit its 52-week high of Rs 1,222. Any Max Healthcare share price target depends on how fast new beds fill up and whether margins recover.

Conclusion

This hospital network stock has created real wealth over five years, rising about 187% on the back of higher revenue per bed, steady occupancy, 22 quarters of growth and a steady flow of acquisitions. The Max Healthcare share price is not a straight-line winner, though, and the 1-year return of -7.74% is a reminder of that.

For long-term investors, the story of this hospital network stock now depends on execution. If the company fills its new towers and margins recover, earnings could catch up with the valuation. If ramp-ups stall, a 69 times earnings multiple leaves this hospital network stock exposed. Track bed additions, occupancy and quarterly margins before taking a position.

Frequently Asked Questions

Which hospital network stock rose 187% in 5 years?

Ans. Max Healthcare Institute Ltd (NSE: MAXHEALTH) is the hospital network stock that gained 187.42% over five years as of 10 September 2026. It ranked 40th among 101 screened NSE stocks for the 5-year period.

What is the Max Healthcare share price today?

Ans. The Max Healthcare share price closed at approximately Rs 1,039 on 10 September 2026. Its 52-week range is around Rs 903 to Rs 1,222, and its market value is approximately Rs 1,00,884 crore.

Why did Max Healthcare share rise over 5 years?

Ans. The rise came from higher revenue per occupied bed, occupancy of around 75%, 22 straight quarters of growth and acquisitions such as Jaypee Healthcare and Kalinga Hospital. FY26 network revenue reached Rs 10,538 crore with profit of Rs 1,631 crore.

Why is Max Healthcare share price down in the last year?

Ans. The stock fell about 7.74% in one year as profit growth slowed to 3% in each of the last two quarters and margins shrank because of new bed costs. Foreign investors also cut their stake from 54.76% to 41.78% in a year.

What is the Max Healthcare share price target?

Ans. Domestic brokerages set targets of Rs 1,120 to Rs 1,162 after the Q1 FY27 results in August 2026. The average target across about 28 analysts is approximately Rs 1,169, roughly 12% above the 10 September close.

How many beds does Max Healthcare plan to add?

Ans. The company had around 6,000 beds at the end of FY26 and targets about 10,000 beds by FY30. Recent approvals include a 712-bed hospital in Lucknow and a 202-bed tower at Vaishali.

Is Max Healthcare share overvalued?

Ans. This hospital network stock trades at around 69 to 70 times trailing earnings, which is expensive by market standards. The valuation assumes new beds fill up quickly, so any slowdown in growth could pressure the stock.

Did Max Healthcare issue a bonus or split its shares?

Ans. No, there was no stock split or bonus issue in the last five years, and the face value remains Rs 10. The 187% return reflects genuine price appreciation.